top of page

MEE N6995 VI, Vision 2.0, The Super-Enhancer that Reverses Acute Kidney Injury (AKI)



Chronic kidney disease is encountered by the primary care physician, in no small part owing to the high rates of hypertension and diabetes, the 2 most common etiologies of chronic kidney disease in the United States. As a physician, it is important to understand the epidemiology, pathophysiology, and evaluation methods of chronic kidney disease. 


Acute Kidney Injury (AKI) is associated with significantly increased mortality, LOS, and costs across a broad spectrum of conditions. Moreover, outcomes are related directly to the severity of AKI, whether characterized by nominal or percentage changes in serum creatinine. Although less obvious to clinicians than severe AKI requiring dialysis, non–dialysis-requiring AKI may be of equal or greater importance from a public health perspective. Prevention and effective treatment of hospital-acquired AKI should be a national priority.


The endogenous repair process can result in recovery after AKI with adaptive proliferation of tubular epithelial cells, but repair can also lead to fibrosis and progressive kidney disease. Meeom Frankfurt R&D Team knows about transcriptional regulators regulating these repair programs. 


Herein we establish the enhancer and super-enhancer landscape after AKI by ChIP-seq in uninjured and repairing kidneys on day two after ischemia reperfusion injury (IRI). We identify key transcription factors including HNF4A, GR, STAT3 and STAT5, which show specific binding at enhancer and super-enhancer sites, revealing enhancer dynamics and transcriptional changes during kidney repair. Loss of bromodomain-containing protein 4 function before IRI leads to impaired recovery after AKI and increased mortality. Our comprehensive analysis of epigenetic changes after kidney injury in vivo has the potential to identify targets for therapeutic intervention. 


MEEOM's Clinically Significant Treatment Response

The MEEOM® approach is inclusive, effective and tailored to the needs of each individual. We do a rigorous assessment with each client at the beginning of treatment, to help us understand the person and the specific problems they want to address through treatment. 


At MEEOM® Precision Medicine, we provide evidence-based treatment plans that are tailored to the particular needs of each patient.


Please send us hospital diagnosis and medical test results.


The German Precision Medicine research team of MEEOM® will decide whether to accept the new case within three working days according to the report.


Healthier, Wealthier & Happier, MEEOM®.


MEEOM® WorldWide Health Systems
MEEOM® Precision Medicine
MEEOM® プレシジョンメディシン

Toll-Free Call 1-833-633-6637 (1833MEEOMER®)

Toll-Free Fax 1-844-633-6637 (1844MEEOMER®)
3-1-1 Kyobashi
Tokyo 104-0031


Facts Talk.


Copyright© 1999-2023 MEEOM® Precision Medicine
AKA "MEEOM® WorldWide Health Systems"
All U.S. and international rights reserved.


1. Charles C, Ferris AH. Chronic Kidney Disease. Prim Care. 2020 Dec;47(4):585-595. 
2. Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V. & Bates, D. W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 16, 3365–3370 (2005).
3. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038–2047 (2007).
4. Wilflingseder, J., Willi, M., Lee, H.K. et al. Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury. Nat Commun 11, 3383 (2020).
5. Rosner, M. H. & Perazella, M. A. Acute kidney injury in patients with cancer. N. Engl. J. Med 376, 1770–1781 (2017).


MEE N6995VI, V2.0 The Super-Enhancer Reverses AKI 腎臓の栄養エネルギー源を強化し、腎不全機能を効果的に逆転させ

SKU: 364215376165719
    bottom of page